It involved 100 patients with severe pancreatitis and confirmed necrosis. Within the first 5 days after onset of symptoms and continuing for 7 to 21 days, 50 patients received 1 g of meropenem intravenously every 8 hours, while the other 50 received placebos.
Participaron 100 pacientes con pancreatitis grave y necrosis confirmada, 50 recibieron meropenem 1 g intravenoso cada 8 horas y 50 placebo, dentro de los 5 primeros días del comienzo de síntomas y durante 7-21 días.